Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements (Tables)

Sponsored Research and Clinical Trial Agreements (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of research and development for sponsored research and clinical trial agreements

For the three and six months ended June 30, 2019 and 2018, Aevitas recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($ in thousands)	2019		2018		2019		2018
UMass – AAV	$	—	$	300	$	—	$	400
UPenn – AAV		250		—		500		—
Total	$	250	$	300	$	500	$	400

Mustang Therapeutics, Inc [Member]

Schedule of research and development for sponsored research and clinical trial agreements

For the three and six months ended June 30, 2019 and 2018, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($ in thousands)	2019		2018		2019		2018
COH CAR T	$	500	$	500	$	1,000	$	1,000
COH - CD123		456		114		759		264
COH - IL13Ra2		225		143		567		503
City of Hope - Manufacturing		115		115		229		229
BIDMC - CRISPR		—		—		69		—
Fred Hutch - CD20		374		418		641		684
Total	$	1,670	$	1,290	$	3,265	$	2,680